Johnson & Johnson

JNJ-N

NYSE:JNJ

140.38
0.82 (0.59%)
Johnson & Johnson is an American multinational medical devices, pharmaceutical and consumer packaged goods manufacturing company founded in 1886.
More at Wikipedia

Analysis and Opinions about JNJ-N

Signal
Opinion
Expert
TOP PICK
TOP PICK
December 5, 2019
The drug space all have huge upsides. He has owned it for quite some time. Model rice is $185.42 which is a 33% upside. There is a lot of value here. (Analysts’ price target is $150.39)
Johnson & Johnson (JNJ-N)
December 5, 2019
The drug space all have huge upsides. He has owned it for quite some time. Model rice is $185.42 which is a 33% upside. There is a lot of value here. (Analysts’ price target is $150.39)
Brian Acker, CA
Chief Executive Officer, President and Chief Inves, Acker Finley Inc.
Price
$139.560
Owned
Yes
DON'T BUY
DON'T BUY
November 21, 2019
JNJ vs PG He'd choose PG. JNJ has lawsuits still hanging around. Since mid-summer of 2018, JNJ has underperformed PG. Watch out for valuations. PG is trading at 24x, with a 7% growth rate. PG is the largest consumer name out there and will continue to grow.
Johnson & Johnson (JNJ-N)
November 21, 2019
JNJ vs PG He'd choose PG. JNJ has lawsuits still hanging around. Since mid-summer of 2018, JNJ has underperformed PG. Watch out for valuations. PG is trading at 24x, with a 7% growth rate. PG is the largest consumer name out there and will continue to grow.
Stan Wong
Director & Portfolio Manager, Private Wealth Management, ScotiaMcleod
Price
$136.440
Owned
No
TOP PICK
TOP PICK
November 19, 2019
It's spent time building a base and is ready to move higher. Yes, headline news is a risk. He believes it will move higher. (Analysts’ price target is $150.39)
Johnson & Johnson (JNJ-N)
November 19, 2019
It's spent time building a base and is ready to move higher. Yes, headline news is a risk. He believes it will move higher. (Analysts’ price target is $150.39)
Elliott Fishman
Director of U.S. and international equity trading, Trading Services Group, Scotia Wealth
Price
$134.820
Owned
Yes
COMMENT
COMMENT
November 7, 2019
High opinion of the company. Will be able to work through legal troubles. One-stop shop with pharma, consumer. Good brand names that will weather the storm. Earnings powerhouse. Good dividend. Short-term bumpiness, but well managed. Yield is 2.9%.
Johnson & Johnson (JNJ-N)
November 7, 2019
High opinion of the company. Will be able to work through legal troubles. One-stop shop with pharma, consumer. Good brand names that will weather the storm. Earnings powerhouse. Good dividend. Short-term bumpiness, but well managed. Yield is 2.9%.
Zachary Curry
Chief Operating Officer & Portfolio Manager, Davis-Rea Ltd.
Price
$131.430
Owned
Unknown
BUY WEAKNESS
BUY WEAKNESS
November 5, 2019

The pharma sector. Any picks? Pharma's problem is the US election cycle when candidates always bash big pharma. But these stocks are not expensive now, like JNJ which boasts 3 divisions (consumer, medical devices and pharma); and Novo Nordisk, which offers a diabetes pill and obesity pill. Buy a small position now as well as when they pull back during the election campaign, and certainly after the election. NVO increases its dividend perennially. The Dems and Republicans are equally critical of pharma.

Johnson & Johnson (JNJ-N)
November 5, 2019

The pharma sector. Any picks? Pharma's problem is the US election cycle when candidates always bash big pharma. But these stocks are not expensive now, like JNJ which boasts 3 divisions (consumer, medical devices and pharma); and Novo Nordisk, which offers a diabetes pill and obesity pill. Buy a small position now as well as when they pull back during the election campaign, and certainly after the election. NVO increases its dividend perennially. The Dems and Republicans are equally critical of pharma.

Paul Harris, CFA
Partner and Portfolio Manager, Harris Douglas Asset Management
Price
$130.420
Owned
Yes
DON'T BUY
DON'T BUY
October 17, 2019
Wouldn't be a buyer at almost any price. Too much of an unknown with asbestos in talc, opioids, etc. Operationally, doing fine. But unknown legal liabilities in front of them, which often lead to a contraction of valuation.
Johnson & Johnson (JNJ-N)
October 17, 2019
Wouldn't be a buyer at almost any price. Too much of an unknown with asbestos in talc, opioids, etc. Operationally, doing fine. But unknown legal liabilities in front of them, which often lead to a contraction of valuation.
Gordon Reid
President, GoodReid Investment Counsel
Price
$137.155
Owned
No
TOP PICK
TOP PICK
October 15, 2019
$170 is his model price, meaning 30% upside. Due to the asbestos lawsuit, this is now a good opportunity. Pays a good dividend. (Analysts’ price target is $148.84)
Johnson & Johnson (JNJ-N)
October 15, 2019
$170 is his model price, meaning 30% upside. Due to the asbestos lawsuit, this is now a good opportunity. Pays a good dividend. (Analysts’ price target is $148.84)
Brian Acker, CA
Chief Executive Officer, President and Chief Inves, Acker Finley Inc.
Price
$132.840
Owned
Yes
COMMENT
COMMENT
October 9, 2019
She's done very well with it. Litigation about opiates is the overhang, and just got a negative ruling on their anti-psychotic drug. Their drugs are doing well, but there are a lot of negative headlines. They may continue selling off troublesome drugs. They remain very profitable but also volatile.
She's done very well with it. Litigation about opiates is the overhang, and just got a negative ruling on their anti-psychotic drug. Their drugs are doing well, but there are a lot of negative headlines. They may continue selling off troublesome drugs. They remain very profitable but also volatile.
Christine Poole
CEO & Managing Director, GlobeInvest Capital Management
Price
$129.220
Owned
Yes
TOP PICK
TOP PICK
October 7, 2019
Heath care stocks have not been in favour. JNJ-N has been in the penalty box with the opioid lawsuits. They only had 1% of the sales in this, however. (Analysts’ price target is $148.53)
Heath care stocks have not been in favour. JNJ-N has been in the penalty box with the opioid lawsuits. They only had 1% of the sales in this, however. (Analysts’ price target is $148.53)
Norman Levine
Managing Director, Portfolio Management Corp
Price
$133.160
Owned
Yes
BUY WEAKNESS
BUY WEAKNESS
September 6, 2019
The talcum and now opiod crisis will continue to cause them to pay out until the regulators are satisfied. He would be a buyer on weakness.
Johnson & Johnson (JNJ-N)
September 6, 2019
The talcum and now opiod crisis will continue to cause them to pay out until the regulators are satisfied. He would be a buyer on weakness.
Darren Sissons
Vice President and Partner, Campbell Lee & Ross
Price
$128.210
Owned
No
DON'T BUY
DON'T BUY
August 27, 2019
The talcum power and opioid issues are being worked out. If you extrapolate what could come from other states, it could become a real issue. There was knowledge on the talcum issue for years. He would stay away from this.
The talcum power and opioid issues are being worked out. If you extrapolate what could come from other states, it could become a real issue. There was knowledge on the talcum issue for years. He would stay away from this.
Don Lato
President, Padlock Investment Management
Price
$129.640
Owned
No
DON'T BUY
DON'T BUY
August 22, 2019
There is a ruling on Monday. This is a great reason not to buy it. Some people think you should not sell it even if you would not buy it if you held it. He would stay clear of it. There is one law suit after another.
There is a ruling on Monday. This is a great reason not to buy it. Some people think you should not sell it even if you would not buy it if you held it. He would stay clear of it. There is one law suit after another.
Gordon Reid
President, GoodReid Investment Counsel
Price
$127.730
Owned
Unknown
BUY
BUY
August 21, 2019
Really a healthcare conglomerate that has medtech and health devices. They also have medical and household products. They are currently trading at a lower multiple, due to the sector being under pressure from legislation. They also have the baby powder lawsuit, which shouldn't be too much of a problem, but the stock price takes a hit when news comes out.
Really a healthcare conglomerate that has medtech and health devices. They also have medical and household products. They are currently trading at a lower multiple, due to the sector being under pressure from legislation. They also have the baby powder lawsuit, which shouldn't be too much of a problem, but the stock price takes a hit when news comes out.
Robert Lauzon
Deputy Chief Investment Officer, Middlefield Capital Corporation
Price
$131.560
Owned
Yes
DON'T BUY
DON'T BUY
August 13, 2019

The PFE-N non-patent drugs will be dilutive for earnings in the short term. She prefers either JNJ-N or ABT-N

The PFE-N non-patent drugs will be dilutive for earnings in the short term. She prefers either JNJ-N or ABT-N

Christine Poole
CEO & Managing Director, GlobeInvest Capital Management
Price
$133.420
Owned
No
TOP PICK
TOP PICK
July 29, 2019
He loves the healthcare space. His model price is over $179. Yield 2.85%
He loves the healthcare space. His model price is over $179. Yield 2.85%
Brian Acker, CA
Chief Executive Officer, President and Chief Inves, Acker Finley Inc.
Price
$133.020
Owned
Yes
Showing 1 to 15 of 431 entries